Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 0.52 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.41 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL326743 | 0.90 | PDE5A (0.44) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL326908 | 0.87 | PDE5A (0.44) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL31120374 | 0.85 | PDE5A (0.39) | PDE5AKMT2A | |
| SCHEMBL25975311 | 0.85 | PDE5A (0.39) | PDE5AKMT2A | |
| SCHEMBL14488284 | 0.85 | PDE5A (0.39) | PDE5A | |
| SCHEMBL29219198 | 0.84 | PDE5A (0.49) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL19151780 | 0.84 | PDE5A (0.50) | PDE5A | |
| SCHEMBL29011924 | 0.84 | PDE5A (0.49) | PDE5AGUCY1A1GUCY1B1MEN1KMT2A | |
| SCHEMBL29219273 | 0.84 | PDE5A (0.49) | PDE5A | |
| SCHEMBL19480643 | 0.83 | PDE5A (0.58) | PDE5AGUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121735952-A | Preparation method of valcigua and intermediate product thereof | 山东齐都药业有限公司 | 2026-03-27 | — | — | CN | disclosed |
| US-20260062411-A1 | NOVEL SALT OF SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND ITS USES | TORRENT PHARMACEUTICALS LTD (IN) | 2026-03-05 | — | — | US | disclosed |
| US-12064429-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2024-08-20 | — | — | US | disclosed |
| WO-2024038398-A1 | NOVEL SALT OF SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND ITS USES | TORRENT PHARMACEUTICALS LIMITED (IN) | 2024-02-22 | — | — | WO | disclosed |
| CN-117567461-A | Preparation method of vitamin Li Xigu intermediate | 佛山奕安赛医药科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20230257398-A1 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | CHIA TAL TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257398-A1 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | CHIA TAL TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20220409618-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | ADVERIO PHARMA GMBH (DE) | 2022-12-29 | — | — | US | disclosed |
| US-20220409618-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | ADVERIO PHARMA GMBH (DE) | 2022-12-29 | — | — | US | disclosed |
| US-11439642-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2022-09-13 | — | — | US | disclosed |
| WO-2012004258-A1 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004258-A1 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004259-A1 | RING-FUSED 4 -AMINOPYRIMIDINES AND USE THEREOF AS STIMULATORS OF SOLUABLE GUANYLATE CYCLASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004259-A1 | RING-FUSED 4 -AMINOPYRIMIDINES AND USE THEREOF AS STIMULATORS OF SOLUABLE GUANYLATE CYCLASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2011161099-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011161099-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011147809-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147809-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147810-A1 | THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147810-A1 | THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12064429-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | PDE5A 121/4885GUCY1A1 1337/4885GUCY1B1 1025/4885 |
| US-11439642-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | PDE5A 121/4885GUCY1A1 1337/4885GUCY1B1 1025/4885 |
| US-20230257398-A1 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | TYMP, TYMS, DPYD | PDE5A 1421/4885GUCY1A1 2940/4885GUCY1B1 2239/4885 |
| US-20260062411-A1 | NOVEL SALT OF SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND ITS USES | PDE3B, PDE5A, PDE2A | PDE5A 2/4885GUCY1A1 9/4885GUCY1B1 26/4885 |
| US-20220409618-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | PFKP, PON1, FABP3 | PDE5A 121/4885GUCY1A1 1337/4885GUCY1B1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.